The day after showing that two of their respective therapies provided better results with earlier treatments, the companies followed up with analyses of safety and brain volume loss for their oral drugs, both of which have already gained significant market share in treating the disease.
Amgen and its partner AstraZeneca are headed to a scientific conference in Istanbul this weekend to lay out a slate of upbeat mid-stage data on a closely-watched psoriasis treatment now in Phase III. Top scientists at both companies say that the interleukin-17 targeting brodalumab continued to reflect the initial promise seen in the first round of Phase II data. And they'll be positioning the drug against a heavily competitive field that includes a heavyweight contender from Novartis.
Novartis pharma chief David Epstein isn't worried about Japanese sales of the blood pressure drug Diovan. He's "much more worried" about the Swiss drugmaker's reputation, now that its Diovan marketing and research are under investigation in Japan. And top-level Novartis managers in Japan are already feeling the effects of that concern.
Novartis' troubles in Japan just keep growing. Now, a government panel is zeroing in on its Diovan advertising. Officials say that the promos may have broken Japanese law--and that could lead to fines and jail terms, Bloomberg reports.
Roche and Novartis may not head to the altar anytime soon--if ever. But the Swiss drugmakers could spend some quality time together. As Roche CEO Severin Schwan said over the weekend, why not collaborate? After all, Roche cooperates with plenty of other rivals.
Swiss drugmaker Novartis has repeatedly apologized after learning that a company employee was affiliated with a study in Japan of blockbuster Diovan as a statistician without revealing his ties to the Swiss healthcare giant. But authorities are not satisfied with apologies and intend to go on-site next week for a closer look.
Novartis is launching the expected blockbuster into a rapidly expanding but increasingly competitive market as established players and newcomers vie for their piece of the action.
Novartis board member Pierre Landolt let a couple of things slip in an interview with the Basler Zeitung published over the weekend. The first is a bit of a head-scratcher: Landolt would like the new chairman of Novartis and Roche to get together for some exploratory merger talk.
Delivering a vaccine against an emerging pandemic flu strain requires developers to make a lot of quick decisions about dosing, use of adjuvants and other factors. With H7N9, however, China's success in limiting the virus' spread has given other countries more time to prepare.
The bribery allegations in China just keep on coming. Novartis' Alcon eyecare division now says it will investigate claims it used fabricated clinical trials to bribe doctors. The news is none too welcome for Novartis, which has already faced a set of bribery accusations in China.